Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation.
A series of 1-[5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines were synthesized and evaluated in vitro against Leishmania major. Most of the target compounds exhibited good anti-leishmanial activity against the promastigote form of L. major at non-cytotoxic concentrations. The most active compound was 1-[(5-chloro-2-thienyl)carbonyl]-4-[5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]piperazine (5f) with an IC(50) value of 9.35+/-0.67 microM against L. major promastigotes. In addition, this compound was effective against intracellular L. major and significantly decreased the infectivity index.
Poorrajab
Fatemeh
F
Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, P.O. Box 13145-1384, Tehran, Iran.
Ardestani
Sussan Kabudanian
SK
Emami
Saeed
S
Behrouzi-Fardmoghadam
Mina
M
Shafiee
Abbas
A
Foroumadi
Alireza
A
D000818:Animals; D015195:Drug Design; D018320:Leishmania major / Q000187:drug effects*; D013830:Thiadiazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D014344:Trypanocidal Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*
D013830:Thiadiazoles; D014344:Trypanocidal Agents; C058949:1,3,4-thiadiazole